Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis

Clinical Therapeutics

Volumn 22, Issue 11, 2000, Pages 1357-1369

  Lofland, Jennifer H ^a,b   Touch, Suzanne M ^a   O'Connor, John P ^a   Chatterton, Mary Lou ^a   Moxey, Elizabeth D ^a   Paddock, Lisa E ^a   Nash, David B ^a   Desai, Shobhana A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cost effectiveness analysis; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; ECONOMIC ASPECT; GESTATIONAL AGE; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MORBIDITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

EID: 0033652584     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)83032-5     Document Type: Article

References (30)

1. Epidemiology of respiratory syncytial virus infection in Washington, DC. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection
2. National surveillance for respiratory syncytial virus, United States, 1985-1990
3. Epidemiology of acute lower respiratory disease in children
4. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race, and sex
5. Respiratory syncytial virus
6. Prospects for immunizing against respiratory syncytial virus
7. Respiratory Syncytial Virus
8. Respiratory syncytial virus activity - United States, 1998-1999 season
9. Continuing mortality and use Of health services by preterm infants after; discharge from hospital
10. Birth weight and hospital readmission of infants born prematurely
11. Rehospitalization of the very-low-birth-weight infant. A continuum of perinatal and environmental morbidity
12. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia
13. The rising national cost of RSV pneumonia in the hospital: US data from 1993-1994
14. Palivizumab, a human respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
15. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
16. Comments on palivizumab
17. Questions about palivizumab
18. Questions about palivizumab
19. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savings
20. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants
21. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation
22. Respiratory Syncytial Virus Immune Globulin Study Group. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG)
23. Special report: Issues and ethics. A cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants
24. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion
25. Respiratory syncytial virus immune globulin intravenous: Indications for use
26. The frequency of respiratory syncytial virus in high-risk infants and the role of palivizumab in prevention of infection
27. Rapid changes for academic medical centers: First of two parts
28. Mother and father interactions over the first year with term and preterm infants
29. Effect of neonatal complications in premature infants on early parent-infant interactions